Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency

Aghamohammadi, Asghar; Farhoudi, A.; Nikzad, Mohsen; Moin, Mostafa; Pourpak, Zahra; Rezaei, Nima; Gharagozlou, Mohammad; Movahedi, Masoud; Atarod, Lida; Afshar, Akefeh Ahmadi; Bazargan, Nasrin; Hosseinpoor, Ahmad Reza

doi:10.1016/s1081-1206(10)61711-5

Cited by 34 publications

(15 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One should not forget both the increased costs and potential adverse effects associated with specific RSV therapy. Immunoglobulins, 31,32 ribavirin, 33 and pavilizumab 34,35 may all have significant adverse effects. In some studies the incidence of serious adverse effects of ribavirin was high, with hemolytic anemia occurring in 61% of treated patients.…”

Section: Discussionmentioning

confidence: 99%

Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy

Uçkay

Gasche-Soccal

Kaiser

et al. 2010

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy

Uçkay

Gasche-Soccal

Kaiser

et al. 2010

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

show abstract

“… 16 – 18 While there is extensive experience with the efficacy of IVIG in common variable immunodeficiency and related PID, there are increasing options for providing therapy, including dose, frequency, and site of care. IVIG therapy dose and residual “trough” IgG levels have been in aggregate correlated with infectious outcomes, 19 – 21 and current practice tends to focus upon individualizing the dosing approach to any given patient.…”

Section: Introductionmentioning

confidence: 99%

Clinical and economic outcomes of a "high-touch" clinical management program for intravenous immunoglobulin therapy

Zhu¹,

Kirkham²,

Ayer³

et al. 2017

CEOR

View full text Add to dashboard Cite

ObjectiveTo compare clinical and economic outcomes of patients who received intravenous immunoglobulin (IVIG) therapies and were managed by a clinical management program vs the outcomes of matched controls using administrative claim data.MethodsThis retrospective cohort study used the PharMetrics Plus™ claim database between September 1, 2011 and June 30, 2014. Patients in the intervention group were from a “high-touch” IVIG clinical management program administered by a home infusion specialty pharmacy. A greedy propensity score matching algorithm was used to identify a control group from non-program patients. Generalized estimating equation models were employed to evaluate differences between cohorts who were followed for 1 year.ResultsClinical outcomes were measured as infections and infusion-related adverse events. The proportion of patients who had serious bacterial infections was significantly lower (4.13% vs 7.75%, P=0.049) in the intervention group (n=242) compared to the control group (n=968). Other clinical outcomes assessed were not different between cohorts (P>0.050). The economic outcomes were measured as healthcare costs. The annual adjusted mean total health care costs of patients in the program were $26,522 lower compared to matched controls, representing a 20% lower cost ($109,476 vs $135,998, P=0.002). A major contribution to this difference ($17,269) was IVIG-related total outpatient cost (intervention vs control groups: $64,080 vs $81,349, P=0.001).ConclusionThe patients in this high-touch IVIG clinical management program appeared to have comparable infections or adverse event rates and significantly lower total health costs compared to their matched controls.

show abstract

“…Early diagnosis, management, and treatment are important, and failure to provide adequate therapy results in tissue and organ damage and various complications (7,17,28). The standard treatment for this disorder is regular immunoglobulin replacement, by either intravenous or subcutaneous administration (2,3,15).…”

mentioning

confidence: 99%

Clinical and Immunological Features of 65 Iranian Patients with Common Variable Immunodeficiency

Aghamohammadi

Farhoudi

Moin

et al. 2005

Clin Vaccine Immunol

Self Cite

112

View full text Add to dashboard Cite

Common variable immunodeficiency (CVID) is a primary immunodeficiency disease characterized by hypogammaglobulinemia and recurrent bacterial infections. The records of 65 patients with CVID (37 males and 28 females) in the age range of 24 to 537 months were reviewed. By the year 2003, 11 patients had died and seven patients could not be located. The total follow-up period was 221 patient-years. The median diagnostic delay (time between onset and diagnosis) in our patient group was 60 months. At the time of diagnosis, the baseline serum immunoglobulin G (IgG), IgM, and IgA levels were below the level normal for the patients' age; the medians for this group were 120, 10, and 0 mg/dl, respectively. All of the patients presented with infectious diseases at the time of onset, the most common of which were otitis media, diarrhea, pneumonia, and sinusitis. Acute and recurrent infections were also found in almost all of the patients, particularly involving respiratory and gastrointestinal systems. The most common infections, before diagnosis and during follow-up, were pneumonia, acute diarrhea, acute sinusitis, and otitis media. CVID should be considered in any patient with a history of recurrent infections and decreased levels of all serum immunoglobulin isotypes.

show abstract

Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency

Cited by 34 publications

References 21 publications

Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy

Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy

Clinical and economic outcomes of a "high-touch" clinical management program for intravenous immunoglobulin therapy

Clinical and Immunological Features of 65 Iranian Patients with Common Variable Immunodeficiency

Contact Info

Product

Resources

About

Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency

Cited by 34 publications

References 21 publications

Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy

Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy

Clinical and economic outcomes of a &quot;high-touch&quot; clinical management program for intravenous immunoglobulin therapy

Clinical and Immunological Features of 65 Iranian Patients with Common Variable Immunodeficiency

Contact Info

Product

Resources

About

Clinical and economic outcomes of a "high-touch" clinical management program for intravenous immunoglobulin therapy